The Effect Of Macitentan On Long-Term Outcomes In Patients With Pulmonary Arterial Hypertension By Who Functional Class: Data From The Randomized Controlled Seraphin Study

被引：0
|
作者：
Channick, R. N. [1 ]
Delcroix, M. [2 ]
Galie, N. [3 ]
Ghofrani, H. A. [4 ,5 ]
Jansa, P. [6 ]
Le Brun, F. O. [7 ]
Mehta, S. [8 ]
Perchenet, L. [7 ]
Pulido, T. [9 ]
Sastry, B. [10 ]
Sitbon, O. [11 ]
Souza, R. [12 ]
Torbicki, A. [13 ]
Rubin, L. J. [14 ]
Simonneau, G. [11 ]
机构：
[1] Massachsetts Gen Hosp, Boston, MA USA
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Univ Bologna, Bologna, Italy
[4] Univers Hosp Giessen & Marburg, German Ctr Lung Res, Giessen, Germany
[5] Imperial Coll London, Giessen, Germany
[6] Charles Univ Prague, Prague, Czech Republic
[7] Actel Pharmaceut Ltd, Allschwil, Switzerland
[8] Western Univ, London Hlth Sci Ctr, Victoria Hosp, London, ON, Canada
[9] Natl Inst Cardiol, Mexico City, DF, Mexico
[10] CARE Hosp, Hyderabad, Andhra Pradesh, India
[11] Univ Paris Sud, Hop Bicetre, Le Kremlin Bicetre, France
[12] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil
[13] ECZ Otwock, Ctr Postgrad Med Educ, Otwock, Poland
[14] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4783
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy
    Simonneau, Gerald
    Channick, Richard
    Delcroix, Marion
    Galie, Nazzareno
    Ghofrani, Hossein
    Jansa, Pavel
    Le Brun, Franck-Olivier
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Sastry, B.
    Sitbon, Olivier
    Souza, Rogerio
    Torbicki, Adam
    Rubin, Lewis
    CHEST, 2013, 144 (04)
  • [22] Macitentan Improves Health-Related Quality Of Life In Pulmonary Arterial Hypertension: Results From The Randomized Controlled Seraphin Trial
    Mehta, S.
    Channick, R. N.
    Delcroix, M.
    Galie, N.
    Ghofrani, H. -A.
    Hunsche, E.
    Jansa, P.
    Le Brun, F. -O.
    Mittelholzer, C.
    Perchenet, L.
    Pulido, T.
    Souza, R.
    Sastry, B.
    Torbicki, A.
    Sitbon, O.
    Rubin, L. J.
    Simonneau, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [23] SUSTAINED EFFECT OF MACITENTAN ON EXERCISE CAPACITY AND THE ASSOCIATION OF ITS MEASURE WITH LONG-TERM OUTCOMES IN PULMONARY ARTERIAL HYPERTENSION
    Whitford, H.
    Galie, N.
    Souza, R.
    Perchenet, L.
    Rubin, L.
    Simonneau, G.
    RESPIROLOGY, 2014, 19 : 29 - 29
  • [24] Long-term outcomes in pulmonary arterial hypertension
    Thenappan, T.
    Palevsky, H. I.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 : 42 - 44
  • [25] EFFECT OF MACITENTAN ON LONG-TERM OUTCOMES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): SUB-ANALYSIS OF SERAPHIN COMPARING INCIDENT AND PREVALENT PATIENT POPULATIONS NOT TREATED WITH PAH-SPECIFIC THERAPY AT BASELINE
    Williams, T.
    Galie, N.
    Perchenet, L.
    Rubin, L.
    Simonneau, G.
    RESPIROLOGY, 2014, 19 : 28 - 28
  • [26] EFFECT OF MACITENTAN ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PULMONARY ARTERIAL HYPERTENSION (PAH): RESULTS FROM THE SERAPHIN RANDOMISED CONTROLLED TRIAL
    Youssef, P.
    Galie, N.
    Perchenet, L.
    Rubin, L.
    Simonneau, G.
    Mehta, S.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 31 - 31
  • [27] Long-term therapeutic outcomes in pulmonary arterial hypertension
    Galie, Nazzareno
    Hirani, Naushad
    Manes, Alessandra
    Romanazzi, Serena
    Palazzini, Massimiliano
    Negro, Luca
    Branzi, Angelo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S11 - S18
  • [28] Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
    Lilla Di Scala
    Marisa Bacchi
    Bjørn Bayer
    Stefano Turricchia
    Advances in Therapy, 2022, 39 : 4346 - 4358
  • [29] Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension: a comparison by etiology and baseline functional class
    Galiè, N.
    Frost, A.
    Keogh, A.
    Zwicke, D.
    Oudiz, R.
    Naeije, R.
    Olschewsky, H.
    Rubin, L.
    EUROPEAN HEART JOURNAL, 2005, 26 : 113 - 113
  • [30] Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (vol 151, pg 106, 2017)
    Mehta, S.
    Sastry, B. K. S.
    Souza, R.
    Torbicki, A.
    Ghofrani, H. A.
    Channick, R. N.
    Delcroix, M.
    Pulido, T.
    Simonneau, G.
    Wlodarczyk, J.
    Rubin, L. J.
    Jansa, P.
    Hunsche, E.
    Galie, N.
    Perchenet, L.
    Sitbon, O.
    CHEST, 2018, 153 (05) : 1287 - 1287
12345